Lists of diseases

EQS-News: Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases

Retrieved on: 
Friday, October 28, 2022
Diamond, Drug discovery, Max Planck Society, Drug development, Villigen, Disease, Gesellschaft mit beschränkter Haftung, Drug design, Probability, GSK, Olaparib, Lists of diseases, Max Planck Institute of Biochemistry, Joint Planning and Development Office, Biology, Science, University College London, Cancer, Gene, Nobel Prize, Genome, Partnership, Pharmaceutical industry, IND, Dodi Protero

Martinsried/Munich, Germany October 25, 2022 Proteros biostructures GmbH (Proteros) today announced that it has initiated a multi-target drug discovery partnership with Adrestia Therapeutics (Cambridge, UK), a leader in synthetic rescue therapies for genetic diseases.

Key Points: 
  • Martinsried/Munich, Germany October 25, 2022 Proteros biostructures GmbH (Proteros) today announced that it has initiated a multi-target drug discovery partnership with Adrestia Therapeutics (Cambridge, UK), a leader in synthetic rescue therapies for genetic diseases.
  • Proteros will provide access to its entire customizable platform of technologies for early drug discovery guided by the companys experienced discovery teams.
  • The partners will jointly discover lead compounds with the goal of further developing them into first-in-class drugs for intractable genetic diseases.
  • Adrestias carefully validated targets, discovered through their unique platform, and their broad potential in disease applications are an inspiration to Proteros.

LARGEST PROVIDER OF ONLINE MENTAL HEALTH TREATMENT AT HIGHER LEVELS OF CARE ANNOUNCES NEW NAME: EATING RECOVERY AT HOME AND PATHLIGHT AT HOME

Retrieved on: 
Thursday, October 27, 2022
MS, National Directorate for Personal Data Protection, Intensive outpatient program, Bulimia nervosa, MD, Mental health, Doctor of Philosophy, Lists of diseases, Life, Depression, ARFID, Binge eating disorder, Partial hospitalization, Family therapy, IOP, Anxiety, Program, Patient, PTSD, Travel, UFED, Quality of life, Education, GLOBE, ERC, Insurance, Mania, Pathlight, Eating recovery, Panic disorder, Anorexia nervosa, Post-traumatic stress disorder, Support, PHP, Home, Eating disorder, Diabulimia, Hospital, Health insurance, Medicine, Residential care

For many people with eating disorders and mood and anxiety disorders, specialized virtual care is key to sustainable recovery.

Key Points: 
  • For many people with eating disorders and mood and anxiety disorders, specialized virtual care is key to sustainable recovery.
  • Thats why, today, Eating Recovery Center and Pathlight Mood & Anxiety Center (ERC Pathlight) announced a new name for their proven virtual intensive outpatient programs (IOP): Eating Recovery At Home and Pathlight At Home.
  • With years of experience rooted in evidence-based mental health care both in-person and online, ERC Pathlight has already brought treatment into the homes of more than 7,000 patients through virtual IOP.
  • Eating Recovery Center (ERC) and Pathlight Mood & Anxiety Center (Pathlight) comprise the nations leading mental health care system dedicated to the treatment of eating disorders and primary mood, anxiety, and trauma-related disorders.

Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial

Retrieved on: 
Thursday, October 27, 2022
Survival, Diabetes, U.S. Securities and Exchange Commission, SEC, Securities Exchange Act of 1934, NPM1, MM, Safety, Cancer, Chronic leukemia, DLBCL, TP53, Risk, CLL, NOTCH1, Patient, Osteopathic medicine in Canada, Board, Multiple myeloma, ALL, ASCO, Research, Rai, GLOBE, B-cell lymphoma, Securities Act of 1933, Lists of diseases, Drug Quality and Security Act, Institutional review board, Chromosome, Vaccine, Pharmaceutical industry

Additional information about the Phase I clinical trial of BMF-219 can be found at ClinicalTrials.gov using the identifier NCT05153330.

Key Points: 
  • Additional information about the Phase I clinical trial of BMF-219 can be found at ClinicalTrials.gov using the identifier NCT05153330.
  • CLL is a chronic leukemia that progresses relatively slowly and typically impacts older adults.
  • Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases.
  • Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Intra-Cellular Therapies to Host Third Quarter 2022 Financial Results Conference Call and Webcast

Retrieved on: 
Thursday, October 27, 2022
Therapy, Company, CNS, Cell, Nobel Prize, Webcast, Investor relations, Psychiatry, GLOBE, Nasdaq, Lists of diseases, Central nervous system, Pharmaceutical industry

To attend the live conference call by phone please use this registration link .

Key Points: 
  • To attend the live conference call by phone please use this registration link .
  • All participants must use the link to complete the online registration process in advance of the conference call.
  • The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com.
  • Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body.

BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022

Retrieved on: 
Thursday, October 27, 2022
Company, SEC, Private Securities Litigation Reform Act, Safety, Lists of diseases, Forward-looking statement, Schizophrenia, Agitation, Bipolar II disorder, Artificial intelligence, Algorithm, Therapy, Prostate cancer, Dementia, Time, Thought disorder, Dexmedetomidine, Pharmaceutical industry

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.

Key Points: 
  • BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.
  • The safety and effectiveness of IGALMI has not been established beyond 24 hours from the first dose.
  • Forward-looking statements in this press release include but are not limited to the date and time of the Companys third quarter 2022 financial results call.
  • These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release.

Aphaia Pharma Announces Enrollment of First Patient in Phase 2 Study of APH-012 for Chronic Weight Management in Individuals with Obesity

Retrieved on: 
Thursday, October 27, 2022
OGTT, University, Business, Hunger, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Obesity, OXM, Medical device, University Medical Center, Patient, Lists of diseases, PYY, Food, Oxyntomodulin, Cohort, Nutritional science, Weight loss, Quality of life, GLOBE, FDA, Appetite, Gastrointestinal tract, Health, Prediabetes, Pharmaceutical industry

APH-012 is designed to restore the intestinal hormone response, which is critical for weight control and metabolic balance.

Key Points: 
  • APH-012 is designed to restore the intestinal hormone response, which is critical for weight control and metabolic balance.
  • The Phase 2 trial ( NCT05385978 ) is a randomized, double-blind, placebo-controlled, proof-of-concept study that will evaluate the safety and efficacy of APH-012 in approximately 150 adults with obesity.
  • Aphaias lead candidate, APH-012, a glucose formulation, has been shown to safely restore endogenous hormone release in individuals with obesity.
  • The versatile design of Aphaias technology platform provides an opportunity for the development of treatments for multiple disease patterns.

Sosei Heptares’ Partner Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia

Retrieved on: 
Friday, October 28, 2022
Pharmacokinetics, Positive and Negative Syndrome Scale, LinkedIn, AstraZeneca, Tokyo Stock Exchange, G protein-coupled receptor, Neurocrine Biosciences, Trial of the century, Safety, Brain, Psychosis, GSK, Novartis, GPCR, Neurology, Patient, AbbVie, Technology, Lists of diseases, Takeda, Tardive dyskinesia, Syndrome, Tissue, Gastroenterology, GLOBE, Twitter, PANSS, FDA, Muscarinic acetylcholine receptor, Population, Time-invariant system, Dementia, Parkinson's disease, Failure, Invention, Intention, Inflammation, Gastrointestinal tract, M1, Pharmaceutical industry, Fine chemical, Neurocrine, Genentech, Schizophrenia, Facebook, M4, Pfizer

NBI-1117568 is an investigational, muscarinic M4 selective acetylcholine receptor agonist believed to be a key regulator of neurotransmitters impacted by schizophrenia.

Key Points: 
  • NBI-1117568 is an investigational, muscarinic M4 selective acetylcholine receptor agonist believed to be a key regulator of neurotransmitters impacted by schizophrenia.
  • The NBI-1117568 Phase 2 multi-arm, multi-stage study will enroll approximately 200 adults and is being conducted at 15 centers throughout the United States.
  • Sosei Heptares retains rights to develop M1 agonists in Japan for any indication, with Neurocrine receiving co-development and profit share options.
  • Sosei Heptares is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).

ClearPoint Neuro to Announce Third Quarter 2022 Results November 8, 2022

Retrieved on: 
Wednesday, October 26, 2022
Therapy, Company, CNS, Security (finance), U.S. Securities and Exchange Commission, Particular, Nasdaq, Lists of diseases, Growth, Brain, Paper, Patient, Quality of life, BD (company), COVID-19, Research, GLOBE, FDA, Telephone, Solution, Biopsy

SOLANA BEACH, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the Company), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2022 third quarter on Tuesday, November 8, 2022, after the market close.

Key Points: 
  • SOLANA BEACH, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the Company), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2022 third quarter on Tuesday, November 8, 2022, after the market close.
  • Investors and analysts are invited to listen to a live broadcast review of the Company's 2022 third quarter on Tuesday, November 8, 2022, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here .
  • The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active sites in the United States, Canada, and Europe.
  • Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements.

Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

Retrieved on: 
Wednesday, October 26, 2022
Neurology, Â, Cytokine, Safety, Lists of diseases, Coronavirus Scientific Advisory Board (Turkey), PET, Immunotherapy, SPMS, Crohn's disease, Program, Patient, Technology, Degenerative disease, News, IV, GLOBE, COVID-19, Foralumab, Autoimmunity, Inflammation, Hospital, Mab, Pharmaceutical industry, Regulatory T cell, Brigham

It will be the first time that non-active Secondary Progressive Multiple Sclerosis patients may receive higher, 100 mcg dosing of intranasal foralumab.

Key Points: 
  • It will be the first time that non-active Secondary Progressive Multiple Sclerosis patients may receive higher, 100 mcg dosing of intranasal foralumab.
  • Given the strong feedback weve received relative to evaluating foralumab in the non-active Secondary Progressive Multiple Sclerosis patient population, I am anticipating swift enrollment of our first patient cohort.
  • Once a day treatment for 10 consecutive days with intranasal foralumab was both well tolerated and produced clinical responses in COVID-19 patients.
  • Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough immunomodulation therapies via novel routes of drug delivery.

Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference

Retrieved on: 
Wednesday, October 26, 2022
Therapy, SEC, Company, R&D, Awareness, Nasdaq, Lists of diseases, Policy, Interest, Patient, Phrase, PTSD, Industry, Multiple sclerosis, Research, GLOBE, Review, Â, Science, SILO, Perception, Nightclub, Pharmaceutical industry, Management

M.B.A, Vice President of R&D, will speak as a panelist at Wonderland: Miami, the largest business gathering in the psychedelic medicine sector.

Key Points: 
  • M.B.A, Vice President of R&D, will speak as a panelist at Wonderland: Miami, the largest business gathering in the psychedelic medicine sector.
  • Silo Pharma is a sponsor of the three-day conference being held November 3-5, 2022, in Miami, Florida.
  • Dr. Kuo will speak on the Mainstream Pharma & Psychedelics panel scheduled for Saturday, November 5th on the Science Main Stage.
  • The panel will discuss Pharmas next trip: The industry alters its state of mind on psychedelics.